Investigator

Contact information:
Tobacco Use Research Center
University of Minnesota
2701 University Avenue, S.E.
Minneapolis, MN 55414
Phone: 612-627-1822
Fax: 612-627-4899
E-mail: moon0078@umn.edu


Marc Mooney, Ph.D., is an Assistant Professor of Psychiatry at the University of Minnesota. Dr. Mooney received his B.A. in psychology from Johns Hopkins University (Phi Beta Kappa). He completed his Doctorate in Clinical Psychology at the University of Minnesota under the supervision of Dr. Dorothy Hatsukami. He completed his clinical internship and post-doctoral fellowship at the University of Texas, Houston. Before coming to the University of Minnesota, he was an assistant professor in the Department of Psychiatry at the University of California, San Francisco.

Dr. Mooney is supported by a National Institute of Drug Abuse (NIDA) Career Development award to advance his research in medications development for smoking cessation. His primary research goal is to create a program for smoking cessation pharmacotherapy development, particularly for complex smokers with psychiatric and substance abuse comorbidities. He is interested in the evaluation of combination or sequential pharmacotherapies as well as novel monotherapies. In conjunction with his program of medication development, he is interested in individual factors that influence medication treatment initiation and completion, including medication knowledge, attitudes, and expectancies. He is also interested in various topics in clinical trials methodology including medication compliance and blinding. He has served as a reviewer for numerous journals including Addiction, Journal of Behavioral Medicine, Drug and Alcohol Review, Nicotine & Tobacco Research, Behavior Therapy, Alcohol and Alcoholism, and Investigational Drugs database. He is an associate editor of the journal Nicotine and Tobacco Research.

Selected Recent Publications

1. Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. Drug Alcohol Depend. In press.
2. Mooney ME, Sayre SL, Hokanson PS, Stotts AL, Schmitz JM. Adding MEMS feedback to behavioral smoking cessation therapy increases compliance with bupropion: A replication and extension study. Addict Behav. In press.
3. Schmitz J, Stotts A, Mooney M, DeLaune K, Moeller FG. Bupropion and cognitive behavioral therapy for smoking cessation in women. Nicotine Tob Res. In press.
4. Mooney M, Green C, Hatsukami D. Nicotine self-administration: cigarette versus nicotine gum diurnal topography. Hum Psychopharmacol 2006;21(8):539-548.
5. Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother 2006;6(7):965-981.
6. Mooney ME, Leventhal AM, Hatsukami DK. Attitudes and knowledge about nicotine and nicotine replacement therapy. Nicotine Tob Res 2006;8(3):435-446.
7. Mooney M, Babb D, Jensen J, Hatsukami D. Interventions to increase use of nicotine gum: A randomized, controlled, single-blind trial. Nicotine Tob Res 2005;7(4):565-579.
8. Schmitz JM, Sayre SL, Stotts AL, Rothfleisch J, Mooney ME. Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback. J Behav Med 2005;28(2):139-147.
9. Mooney M, Sayre SL, Green C, Rhoades H, Schmitz J. Comparing measures of medication taking in a pharmacotherapy trial for cocaine dependence. Addictive Disorders & Their Treatment 2004;3(4):165-173.
10. Mooney M, White T, Hatsukami D. The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. Addictive Behaviors 2004;29(4):673-684.